- Home
- ALGS vs AKTX Comparison
ALGS vs AKTX Comparison
Compare ALGS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- AKTX
- Stock Information
- Founded
- ALGS 2018
- AKTX N/A
- Country
- ALGS United States
- AKTX United States
- Employees
- ALGS N/A
- AKTX N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- AKTX Health Care
- Exchange
- ALGS Nasdaq
- AKTX Nasdaq
- Market Cap
- ALGS 50.4M
- AKTX 41.8M
- IPO Year
- ALGS 2020
- AKTX N/A
- Fundamental
- Price
- ALGS $7.84
- AKTX N/A
- Analyst Decision
- ALGS Strong Buy
- AKTX
- Analyst Count
- ALGS 1
- AKTX 0
- Target Price
- ALGS $70.00
- AKTX N/A
- AVG Volume (30 Days)
- ALGS 125.8K
- AKTX 28.5K
- Earning Date
- ALGS 08-05-2025
- AKTX 08-18-2025
- Dividend Yield
- ALGS N/A
- AKTX N/A
- EPS Growth
- ALGS N/A
- AKTX N/A
- EPS
- ALGS N/A
- AKTX N/A
- Revenue
- ALGS $3,270,000.00
- AKTX N/A
- Revenue This Year
- ALGS N/A
- AKTX N/A
- Revenue Next Year
- ALGS $51.55
- AKTX N/A
- P/E Ratio
- ALGS N/A
- AKTX N/A
- Revenue Growth
- ALGS N/A
- AKTX N/A
- 52 Week Low
- ALGS $3.76
- AKTX $0.85
- 52 Week High
- ALGS $46.80
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- ALGS 57.02
- AKTX 41.94
- Support Level
- ALGS $6.82
- AKTX $1.10
- Resistance Level
- ALGS $8.66
- AKTX $1.18
- Average True Range (ATR)
- ALGS 0.76
- AKTX 0.07
- MACD
- ALGS -0.06
- AKTX 0.00
- Stochastic Oscillator
- ALGS 55.49
- AKTX 35.50
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.